Ian Catlett, PhD

Bristol Meyers Squibb
Pennington, NJ, United States

Senior Director of Clinical Biomarkers and Translational Medicine, Therapeutic Area Head Dermatology and Rheumatology

Disclosure information not submitted.

Presentation(s):

• 1000: Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study

  Sunday, November 13, 2022
  9:00 AM – 10:30 AM Eastern Time

• 1000: Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study

  Monday, November 14, 2022
  1:45 PM – 1:50 PM Eastern Time